文献リスト

1）Chu CM, Liaw YF. HBsAg seroclearance in asymptomatic carriers of high endemic areas: appreciably high rates during a long-term follow-up. Hepatology. 2007; 45: 1187-92

2）Kobayashi M, Hosaka T, Suzuki F, et al. Seroclearance rate of hepatitis B surface antigen in 2,112 patients with chronic hepatitis in Japan during long-term follow-up. J Gastroenterol. 2013. In print

3）Hosaka T, Suzuki F, Kobayashi M, et al. Clearance of hepatitis B surface antigen during long-term nucleot(s)ide analog treatment in chronic hepatitis B: results from a nine-year longitudinal study. J Gastroenterol. 2013; 48: 930-41

4）Belloni L, Allweiss L, Guerrieri F, et al. IFN-alpha inhibits HBV transcription and replication in cell culture and in humanized mice by targeting the epigenetic regulation of the nuclear cccDNA minichromosome. J Clin Invest. 2012; 122: 529-37

5）Belloni L, Pollicino T, De Nicola F, et al. Nuclear HBx binds the HBV minichromosome and modifies the epigenetic regulation of cccDNA function. Proc Natl Acad Sci U S A. 2009; 106: 19975-9

6）Pollicino T, Belloni L, Raffa G, et al. Hepatitis B virus replication is regulated by the acetylation status of hepatitis B virus cccDNA-bound H3 and H4 histones. Gastroenterology. 2006; 130: 823-37

7）Kumada H, Okanoue T, Onji M, et al. Guidelines for the treatment of chronic hepatitis and cirrhosis due to hepatitis B virus infection for the fiscal year 2008 in Japan. Hepatol Res. 2010; 40: 1-7

8）Idilman R, Cinar K, Seven G, et al. Hepatitis B surface antigen seroconversion is associated with favourable long-term clinical outcomes during lamivudine treatment in HBeAg-negative chronic hepatitis B patients. J Viral Hepat. 2012; 19: 220-6

9）Kittner JM, Sprinzl MF, Grambihler A, et al. Adding pegylated interferon to a current nucleos(t)ide therapy leads to HBsAg seroconversion in a subgroup of patients with chronic hepatitis B. J Clin Virol. 2012; 54: 93-5

10）Lampertico P, Vigano M, Cheroni C, et al. IL28B polymorphisms predict interferon-related hepatitis B surface antigen seroclearance in genotype D hepatitis B e antigen-negative patients with chronic hepatitis B. Hepatology. 2013; 57: 890-6

11）Marcellin P, Bonino F, Lau GK, et al. Sustained response of hepatitis B e antigen-negative patients 3 years after treatment with peginterferon alpha-2a. Gastroenterology. 2009; 136: 2169-79 e1-4

12）朝比奈靖浩，泉　並木，桶谷　眞，他．B型肝炎治療ガイドライン（第1.1版）．2013

13）熊田博光. 厚生労働科学研究費補助金　肝炎等克服緊急対策研究事業 「ウイルス性肝炎における最新の治療法の標準化を目指す研究に関する研究班」平成24年度　総括・分担研究報告書 2013

14）Hosaka T, Suzuki F, Kobayashi M, et al. Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection. Hepatology. 2013; 58: 98-107

15）Chevaliez S, Hezode C, Bahrami S, et al. Long-term hepatitis B surface antigen (HBsAg) kinetics during nucleoside/nucleotide analogue therapy: Finite treatment duration unlikely. J Hepatol. 2013; 58: 676-83

16）Tseng TC, Kao JH. Clinical utility of quantitative HBsAg in natural history and nucleos(t)ide analogue treatment of chronic hepatitis B: new trick of old dog. J Gastroenterol. 2013; 48: 13-21

17）Yokosuka O, Takaguchi K, Fujioka S, et al. Long-term use of entecavir in nucleoside-naive Japanese patients with chronic hepatitis B infection. J Hepatol. 2010; 52: 791-9

18）Ono A, Suzuki F, Kawamura Y, et al. Long-term continuous entecavir therapy in nucleos(t)ide-naive chronic hepatitis B patients. J Hepatol. 2012; 57: 508-14

19）Zoulim F, Locarnini S. Hepatitis B virus resistance to nucleos(t)ide analogues. Gastroenterology. 2009; 137: 1593-608 e1-2

20）Mitsui F, Tsuge M, Kimura T, et al. Importance of serum concentration of adefovir for Lamivudine-adefovir combination therapy in patients with lamivudine-resistant chronic hepatitis B. Antimicrob Agents Chemother. 2010; 54: 3205-11

21）Tanaka M, Suzuki F, Seko Y, et al. Renal dysfunction and hypophosphatemia during long-term lamivudine plus adefovir dipivoxil therapy in patients with chronic hepatitis B. J Gastroenterol. 2013. In print

22）Wu C, Zhang H, Qian Y, et al. Hypophosphatemic osteomalacia and renal Fanconi syndrome induced by low-dose adefovir dipivoxil: a case report and literature review suggesting ethnic predisposition. J Clin Pharm Ther. 2013; 38: 321-6

23）Suzuki F, Arase Y, Suzuki Y, et al. Long-term efficacy of interferon therapy in patients with chronic hepatitis B virus infection in Japan. J Gastroenterol. 2012; 47: 814-22

24）de Niet A, Takkenberg RB, Benayed R, et al. Genetic variation in IL28B and treatment outcome in HBeAg-positive and -negative chronic hepatitis B patients treated with Peg interferon alfa-2a and adefovir. Scand J Gastroenterol. 2012; 47: 475-81

25）Takkenberg B, Terpstra V, Zaaijer H, et al. Intrahepatic response markers in chronic hepatitis B patients treated with peginterferon alpha-2a and adefovir. J Gastroenterol Hepatol. 2011; 26: 1527-35

26）Takkenberg RB, Jansen L, de Niet A, et al. Baseline hepatitis B surface antigen (HBsAg) as predictor of sustained HBsAg loss in chronic hepatitis B patients treated with peginterferon alfa-2a and adefovir. Antivir Ther. 2013. In print

27）Pan X, Zhang K, Yang X, et al. Relapse rate and associated-factor of recurrence after stopping NUCs therapy with different prolonged consolidation therapy in HBeAg positive CHB patients. PLoS One. 2013; 8: e68568

28）厚生労働科学研究費補助金．肝炎等克服緊急対策研究事業 「B型肝炎の核酸アナログ薬治療における治療中止基準の作成と治療中止を目指したインターフェロン治療の有用性に関する検討」平成21～23年度総合研究報告書．2012. p.16-8

29）Matsumoto A, Tanaka E, Suzuki Y, et al. Combination of hepatitis B viral antigens and DNA for prediction of relapse after discontinuation of nucleos(t)ide analogs in patients with chronic hepatitis B. Hepatol Res. 2012; 42: 139-49

30）Zoutendijk R, Reijnders JG, Zoulim F, et al. Virological response to entecavir is associated with a better clinical outcome in chronic hepatitis B patients with cirrhosis. Gut. 2013; 62: 760-5

31）Karatayli E, Karatayli SC, Cinar K, et al. Molecular characterization of a novel entecavir mutation pattern isolated from a multi-drug refractory patient with chronic hepatitis B infection. J Clin Virol. 2012; 53: 130-4

32）Song ZL, Cui YJ, Zheng WP, et al. Diagnostic and therapeutic progress of multi-drug resistance with anti-HBV nucleos(t)ide analogues. World J Gastroenterol. 2012; 18: 7149-57

33）Lavocat F, Deny P, Pichoud C, et al. Similar evolution of Hepatitis B virus quasispecies in patients with incomplete adefovir response receiving tenofovir/emtricitabine combination or tenofovir monotherapy. J Hepatol. 2013; 59: 684-95

34）Seto WK, Liu K, Wong DK, et al. Patterns of hepatitis B surface antigen decline and HBV DNA suppression in Asian treatment-experienced chronic hepatitis B patients after three years of tenofovir treatment. J Hepatol. 2013; 59: 709-16

35）Baran B, Soyer OM, Ormeci AC, et al. Efficacy of tenofovir in patients with Lamivudine failure is not different from that in nucleoside/nucleotide analogue-naive patients with chronic hepatitis B. Antimicrob Agents Chemother. 2013; 57: 1790-6

36）Gordon SC, Krastev Z, Horban A, et al. Efficacy of tenofovir disoproxil fumarate at 240 weeks in patients with chronic hepatitis B with high baseline viral load. Hepatology. 2013; 58: 505-13

37）Fernandez-Fernandez B, Montoya-Ferrer A, Sanz AB, et al. Tenofovir nephrotoxicity: 2011 update. AIDS Res Treat. 2011; 354908

38）Gracey DM, Snelling P, McKenzie P, et al. Tenofovir-associated Fanconi Syndrome in patients with chronic hepatitis B monoinfection. Antivir Ther. 2013. In print

39）Hall AM. Update on tenofovir toxicity in the kidney. Pediatr Nephrol. 2013; 28: 1011-23

40）Mauss S, Berger F, Filmann N, et al. Effect of HBV polymerase inhibitors on renal function in patients with chronic hepatitis B. J Hepatol. 2011; 55: 1235-40

NPO医学中央雑誌刊行会 https://www.jamas.or.jp/ info@jamas.or.jp